PS1-11-09

Real-world Prevalence of *ESR1* Mutations Among Patients With ER+/HER2- Metastatic Breast Cancer After First-line Treatment With Endocrine Therapy and/or a CDK4/6 Inhibitor

David Chandiwana,[1] Darrin Benjumea,[2] Kaitlin Greco,[1] Chloe Grace Rose,[3] Stella Stergiopoulos,[3] Jiemin Liao,[4] Michelle Edwards[1]

[1]Arvinas Operations, Inc., New Haven, CT; [2]Genesis Research Group, Hoboken, NJ; [3]Pfizer, Inc., New York City, NY; [4]Guardant Health, Palo Alto, CA

Objective

- To evaluate the real-world prevalence of estrogen receptor (ER) 1 gene mutations (*ESR1*m) and co-occurring mutations after first-line (1L) treatment with endocrine therapy (ET) and/or a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) among patients with ER+, human epidermal growth factor receptor (HER2)-metastatic breast cancer (MBC)

Key Findings

- Among 1,511 patients in the GuardantINFORM database considered evaluable for *ESR1*m, 45.4% had an *ESR1*m detected in circulating tumor DNA (ctDNA) at or before start of second-line (2L) therapy
- The majority of patients had received 1L treatment with an aromatase inhibitor (AI) or selective ER modulator (SERM) in combination with a CDK4/6i (33.1%) or as monotherapy (26.5%)
  - *ESR1m* were detected in a greater proportion of patients treated 1L with an AI/SERM + CDK4/6i (48.4%) vs AI/SERM monotherapy (38.3%)
- Patients who received 1L treatment for longer durations tended to have higher rates of *ESR1*m positivity, with the highest rates observed following 1L treatment of 12 to 24 months (54.9%)
- Most patients (67.9%) with *ESR1*m-positive ctDNA also tested positive for ≥1 other oncogenic gene alteration of interest (*PIK3CA*, *PTEN*, *AKT1 E17K*, *CCND1*, *ERBB2*, *FGFR1*, *KRAS*, *MYC*, *NF1*, and/or *RB1*)

Conclusions

- This real-world analysis showed frequent occurrence of *ESR1*m after 1L endocrine-based therapy across treatment types and durations, reflecting emerging resistance in a sizeable subgroup of patients with ER+/HER2- MBC that may benefit from more targeted forms of therapy
- The high rates of co-occurring oncogenic gene alterations underscore the need for comprehensive genomic testing to guide next-line treatment decisions

References

1. Li Y, et al. JAMA Netw Open. 2020;3(1):e1918160.
2. Cardoso F, et al. Ann Oncol. 2020;31(12):1623-1649.
3. Burstein HJ, et al. J Clin Oncol. 2024; 42 (12):1450-1453.
4. Hanker AB, et al. Cancer Cell. 2020;37(4):496-513.
5. Wander SA, et al. Cancer Discov. 2020;10(8):1174-93.
6. Bidard FC, et al. J Clin Oncol. 2022;40(28):3246-56.
7. Bardia A, et al. J Clin Oncol. 2021;39(12):1360-70.
8. Chaudhary N, et al. npj Breast Cancer. 2024;10(1):15.
9. Chandarlapaty S, et al. JAMA Oncol. 2016;2(10):1310.
10. Venetis K, et al. Cancer Treat Rev. 2023;121:102642.

Acknowledgments

This study was sponsored by Arvinas Estrogen Receptor, Inc in collaboration with Pfizer Inc. Medical writing support was provided by Lela Creutz, PhD of Arvinas Operations, Inc.

Contact

David Chandiwana: david.chandiwana@arvinas.com

Scan this QR code to view a copy of this poster.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SABCS® and the author.

San Antonio Breast Cancer Symposium (SABCS)
San Antonio, TX, USA; December 9-12, 2025

Background

- Approximately 70% of patients with breast cancer have ER+/HER2- tumors[1]
- Combination therapy with ET and a CDK4/6i is standard 1L therapy for patients with ER+/HER2- MBC[2,3]
- While this approach is initially effective, treatment resistance develops in most patients, often due to the emergence of genetic alterations in tumor cells, including *ESR1*m[4,5]
- Reported *ESR1*m prevalence rates vary widely (~20% to 50%) after ≥1 line of treatment in the metastatic setting[6-9]
- The variability in reported rates is attributable to multiple factors, including heterogeneity among patient cohorts (eg, prior duration and setting of ET)
- To better understand the real-world prevalence of *ESR1*m and co-occurring gene alterations, we evaluated the prevalence of these mutations after receiving 1L ET and/or a CDK4/6i among patients with ER+/HER2- MBC in the GuardantINFORM database

Methods

- This noninterventional, retrospective analysis identified patients in the GuardantINFORM database in the United States who received ≥1 Guardant360 liquid biopsy test between January 1, 2014, and June 30, 2024
- Patients were included in the analysis population if they had received any of the following 1L treatments within 6 months of diagnosis of metastatic disease:
  - Endocrine monotherapy (AI, selective ER modulator [SERM], or SERD), or
  - CDK4/6i monotherapy, or
  - Combination treatment with ET (AI, SERM, and/or SERD) and a CDK4/6i
- Patients must have discontinued their 1L therapy and subsequently received 2L treatment
- The *ESR1*-evaluable population included patients with an *ESR1*-negative test result ≤90 days before initiating 2L therapy (to exclude patients who may have been tested preceding the potential development of resistance to 1L treatment) or a positive *ESR1*m result at any time before starting 2L therapy
- The *ESR1*-evaluable population included patients with ctDNA-positive and ctDNA-negative samples; 91.7% of the population tested were ctDNA-positive
  - A subgroup analysis of patients with only ctDNA-positive samples showed that trends were consistent with the overall population (data not shown)
- The proportion of *ESR1*-evaluable patients who were *ESR1*m positive (any missense mutation in codons 310–547 detected in ctDNA)[10] was analyzed in the overall *ESR1*-evaluable population and by the type and duration of 1L treatment
- Other oncogenic alterations linked to endocrine and/or CDK4/6i resistance were quantified, including *PIK3CA* mutations (R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L, G1049R), *PTEN*, *AKT1* E17K, *CCND1* alterations (including amplifications), *ERBB2, FGFR1* (including fusions and amplifications), *KRAS* (including amplifications), *MYC* (including amplifications), *NF1,* and *RB1*

Results

Study population

- A total of 8,335 adults in the GuardantINFORM database met initial screening criteria and initiated 1L ET and/or a CDK4/6i (**Table 1**)
- Of these, 1,511 patients had either a positive *ESR1*m test result anytime prior to starting 2L therapy or a negative *ESR1*m test result within 90-days of starting 2L therapy – these patients were considered to have *ESR1*m testing proximally to start of 2L therapy and were the primary cohort for these analyses

Table 1: Cohort attrition


Step	Eligibility Criteria	No. of patients remaining	% of patients from previous step
1	CGP testing by a Guardant360 test on a sample with 2 distinct dates or encounters from Jan 1, 2014 to Jun 30, 2024 and MBC diagnosis code (ICD-9-CM and ICD-10-CM)	33,774	–
2	≥6 months of continuous medical and drug enrollment prior to date of MBC diagnosis	26,050	77.1%
3	Age ≥18 years and received 1L treatment with ET and/or a CDK4/6i within 6-months of the MBC diagnosis date (proxy for ER+ status), excluding other drug combinations	11,186	42.9%
4	Continuous medical and drug enrollment from date of MBC diagnosis to start of 1L therapy	11,146	99.6%
5	No other reasons for exclusion[a]	8,335	74.8%
6	*ESR1*-negative test result ≤90 days before initiating 2L therapy (to rule out false negatives from early testing preceding development of resistance) or a positive *ESR1*m test result any time before starting 2L therapy	1,511	18.1%

[a]Reasons for exclusion included (1) conflicting information between claim dates, test dates and death dates, (2) evidence (≥2 claims) of treatment for HER2+ disease (lapatinib, tucatinib, neratinib, trastuzumab, fam-trastuzumab deruxtecan-nxki, pertuzumab), (3) diagnosis of other primary cancers, other than non-melanoma skin cancer during the lookback period using ICD-9-CM and ICD-10-CM diagnosis codes, or (4) enrollment in a clinical trial during the study period, identified via ICD-9-CM and ICD-10-CM diagnosis codes.
1L=first-line; 2L=second-line; CDK4/6i=cyclin-dependent kinase 4/6 inhibitor; CGP=comprehensive genomic profiling; ER=estrogen receptor; ET=endocrine therapy; *ESR1*m=ER 1 gene mutation; HER2=human epidermal growth factor receptor 2; ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; MBC=metastatic breast cancer.

*ESR1*m positivity by type of 1L therapy

- Among all *ESR1*-evaluable patients, 45.4% had an *ESR1*m detected in ctDNA at or before start of 2L therapy (**Figure 1**)
- The majority of patients had received 1L therapy with an AI or SERM in combination with a CDK4/6i (33.1%; 500/1,511) or as monotherapy (26.5%; 400/1,511)
  - The *ESR1*m positivity rate was higher among patients treated with an AI/SERM plus a CDK4/6i (48.4%) vs AI/SERM monotherapy (38.3%; **Figure 1**)
- Approximately one third of patients had received a SERD as 1L therapy for MBC, either in combination with a CDK4/6i and/or an AI/SERM (19.8%; 299/1,511) or as monotherapy (12.2%; 185/1,511)
  - *ESR1*m were detected in 51.6% to 52.4% of patients who received a SERD as monotherapy or in combination with an AI/SERM ± CDK4/6i (**Figure 1**)

Figure 1: *ESR1*m positivity at or before start of 2L treatment[a] by type of 1L treatment received




[a]Patients could have tested positive for *ESR1*m at any time, including prior to or during or 1L treatment. Treatments received prior to MBC diagnosis (ie, adjuvant) are not known.
1L=first-line; 2L=second-line; AI=aromatase inhibitor;CDK4/6i=cyclin dependent kinase 4/6 inhibitor; *ESR1*m=estrogen receptor 1 gene mutation; SERD=selective estrogen receptor degrader; SERM=selective estrogen receptor modulator.

*ESR1*m positivity by duration of 1L therapy

- Patients who had received 1L therapy for longer durations tended to have higher *ESR1*m rates, with the highest rates observed among patients treated 1L for 12 to <24 months (54.9%; **Figure 2A**)
- This trend was consistent across most 1L therapy types (**Figure 2B**)
  - *ESR1*m rates were lowest among those treated 1L with AI or SERM monotherapy for <6 months (24.1%) and highest among patients who received 1L SERD monotherapy for 12 to <24 months (67.9%)
  - Across most 1L therapy types, *ESR1*m rates were lower among patients treated for ≥36 months vs 12 to <24 months, possibly due to the small populations in these subgroups

Figure 2: *ESR1*m positivity[a] by duration 1L treatment




[a]Patients could have tested positive for *ESR1*m at any time, including prior to or during or 1L treatment. Treatments received prior to MBC diagnosis (ie, adjuvant) are not known.
1L=first-line;; AI=aromatase inhibitor;CDK4/6i=cyclin dependent kinase 4/6 inhibitor; *ESR1*m=estrogen receptor 1 gene mutation; SERD=selective estrogen receptor degrader; SERM=selective estrogen receptor modulator.

Co-occurring mutations

- Among all 1,511 *ESR1*-evaluable patients, 58.5% had ≥1 other oncogenic gene alteration detected in ctDNA (**Figure 3**)
- The proportion of patients with ≥1 other gene alteration was higher among patients with *ESR1*m-positive (67.9%) vs *ESR1*m-negative ctDNA (50.7%)
- *PIK3CA* mutations were the most common other alteration among patients with *ESR1*m-positive (43.0%) and *ESR1*m-negative ctDNA (33.2%)

Figure 3: Prevalence of other gene alterations of interest



[a]Patients could have tested positive for *ESR1*m at any time, including prior to or during or 1L treatment. Treatments received prior to MBC diagnosis (ie, adjuvant) are not known.
1L=first-line; *ESR1*m=estrogen receptor 1 gene mutation; WT=wild-type,

Limitations

- This analysis is subject to the limitations inherent to retrospective database analyses, including the potential for missing information and misclassification
- Potential misclassifications could include MBC status, ER and HER2 status, and timing of the start and end of 1L and 2L therapies
- There is a potential for selection bias, as only patients who underwent ≥1 Guardant360 liquid biopsy test were included; the analysis population may not represent the broader population of cancer patients, especially those who received other types of liquid biopsy or tumor tissue-based biopsy only
- Patients could have tested positive for *ESR1*m at any time, including prior to starting 1L therapy for MBC, and prior therapies received for non-metastatic disease (eg, neoadjuvant ET) are unknown; thus, the relatively high *ESR1*m rate among patients treated 1L with SERDs may be partially due to SERDs being prescribed for MBC that was *ESR1*m-positive at or before start of 1L therapy